Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals (NQ: SYRS )

5.980 +0.350 (+6.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 73,626
Open 5.690
Bid (Size) 5.500 (3)
Ask (Size) 5.980 (3)
Prev. Close 5.630
Today's Range 5.530 - 6.060
52wk Range 2.090 - 8.170
Shares Outstanding 20,595,503
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
SYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024
SYRS stock results show that Syros Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-23.72%
-23.72%
1 Month
+13.90%
+13.90%
3 Month
+1.01%
+1.01%
6 Month
-18.19%
-18.19%
1 Year
+84.57%
+84.57%

More News

Read More
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Participate in Upcoming Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals's Earnings Outlook
Via Benzinga
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
From Syros Pharmaceuticals
Via Business Wire
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
From Syros Pharmaceuticals
Via Business Wire
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Syros Pharmaceuticals
Via Business Wire
Top 3 Health Care Stocks You'll Regret Missing This Month
Via Benzinga
SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
From Syros Pharmaceuticals
Via Business Wire
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
From Syros Pharmaceuticals
Via Business Wire
Earnings Scheduled For March 27, 2024
Via Benzinga
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
From Syros Pharmaceuticals
Via Business Wire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Syros to Participate in TD Cowen 44th Annual Health Care Conference
From Syros Pharmaceuticals
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
Via InvestorPlace
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene
From Syros Pharmaceuticals
Via Business Wire
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.